Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China

IntroductionFirst-line treatment with tislelizumab plus chemotherapy has shown clinical benefits for patients with advanced or metastatic esophageal squamous cell carcinoma (OSCC) in China, while its economic burden is unknown. This study aimed to evaluate the cost-effectiveness of tislelizumab plus...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Yanhong Liu, Rong Shao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-05-01
Subjects:	cost-effectiveness analysis tislelizumab advanced OSCC Chinese healthcare system partitioned survival model
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1225076/full